marked.bio

β-catenin antagonist · peptide

ST316

1 active trials, targeting β-catenin/BCL9. Not approved for any biomarker on marked.bio yet.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
BRCA1/2 mutation 1 1 Phase 1

Sponsors

Industry sponsors leading active biomarker-selected trials of ST316.

  1. Sapience Therapeutics 1

Trials

1 of 1 trials shown

  1. A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors

    Active, not recruiting Phase 1 Sapience Therapeutics Started 2023Primary completion 2026-12 NCT05848739

    ST316FOLFIRIbevacizumab FDA EUfruquintinibtrifluridine/tipiracil

    Subjects with TNBC or OC with known BRCA mutations must have been previously treated with or intolerant to Food and Drug Administration (FDA…

    BRCA1/2 mutationColon Cancer, Metastatic Colon Cancer